Logo image of HYPD

HYPERION DEFI INC (HYPD) Stock Fundamental Analysis

NASDAQ:HYPD - US30234E2037 - Common Stock

6.16 USD
+0.06 (+0.98%)
Last: 8/22/2025, 8:14:21 PM
6.59 USD
+0.43 (+6.98%)
After Hours: 8/22/2025, 8:14:21 PM
Fundamental Rating

1

Taking everything into account, HYPD scores 1 out of 10 in our fundamental rating. HYPD was compared to 193 industry peers in the Pharmaceuticals industry. HYPD has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, HYPD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HYPD has reported negative net income.
In the past year HYPD has reported a negative cash flow from operations.
HYPD had negative earnings in each of the past 5 years.
In the past 5 years HYPD always reported negative operating cash flow.
HYPD Yearly Net Income VS EBIT VS OCF VS FCFHYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of HYPD (-708.22%) is worse than 95.85% of its industry peers.
Industry RankSector Rank
ROA -708.22%
ROE N/A
ROIC N/A
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HYPD Yearly ROA, ROE, ROICHYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HYPD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HYPD Yearly Profit, Operating, Gross MarginsHYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K

More info and screens

0

2. Health

2.1 Basic Checks

HYPD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HYPD has been increased compared to 1 year ago.
HYPD has more shares outstanding than it did 5 years ago.
HYPD has a worse debt/assets ratio than last year.
HYPD Yearly Shares OutstandingHYPD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
HYPD Yearly Total Debt VS Total AssetsHYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

HYPD has an Altman-Z score of -63.86. This is a bad value and indicates that HYPD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -63.86, HYPD is doing worse than 93.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.86
ROIC/WACCN/A
WACC11.31%
HYPD Yearly LT Debt VS Equity VS FCFHYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

HYPD has a Current Ratio of 0.34. This is a bad value and indicates that HYPD is not financially healthy enough and could expect problems in meeting its short term obligations.
HYPD's Current ratio of 0.34 is on the low side compared to the rest of the industry. HYPD is outperformed by 95.34% of its industry peers.
A Quick Ratio of 0.34 indicates that HYPD may have some problems paying its short term obligations.
With a Quick ratio value of 0.34, HYPD is not doing good in the industry: 94.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34
HYPD Yearly Current Assets VS Current LiabilitesHYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.07% over the past year.
Looking at the last year, HYPD shows a very strong growth in Revenue. The Revenue has grown by 781.58%.
The Revenue for HYPD have been decreasing by -84.00% on average. This is quite bad
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%200%

3.2 Future

HYPD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.36% yearly.
The Revenue is expected to grow by 250.09% on average over the next years. This is a very strong growth
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5YN/A
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HYPD Yearly Revenue VS EstimatesHYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 10M 20M 30M
HYPD Yearly EPS VS EstimatesHYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HYPD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HYPD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYPD Price Earnings VS Forward Price EarningsHYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYPD Per share dataHYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as HYPD's earnings are expected to grow with 20.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.63%
EPS Next 3Y20.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HYPD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYPERION DEFI INC

NASDAQ:HYPD (8/22/2025, 8:14:21 PM)

After market: 6.59 +0.43 (+6.98%)

6.16

+0.06 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners13.16%
Inst Owner ChangeN/A
Ins Owners9.44%
Ins Owner Change68.49%
Market Cap35.05M
Analysts47.5
Price TargetN/A
Short Float %6.93%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.5%
Min EPS beat(2)5.64%
Max EPS beat(2)83.35%
EPS beat(4)3
Avg EPS beat(4)17.71%
Min EPS beat(4)-37.25%
Max EPS beat(4)83.35%
EPS beat(8)5
Avg EPS beat(8)6.62%
EPS beat(12)7
Avg EPS beat(12)7.27%
EPS beat(16)10
Avg EPS beat(16)16.18%
Revenue beat(2)0
Avg Revenue beat(2)-96.53%
Min Revenue beat(2)-96.75%
Max Revenue beat(2)-96.32%
Revenue beat(4)0
Avg Revenue beat(4)-97.42%
Min Revenue beat(4)-99.04%
Max Revenue beat(4)-96.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 523.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-34.16
EYN/A
EPS(NY)-26.52
Fwd EYN/A
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-4.34
OCFYN/A
SpS0.01
BVpS-1.71
TBVpS-1.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -708.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z -63.86
F-Score3
WACC11.31%
ROIC/WACCN/A
Cap/Depr(3y)219.51%
Cap/Depr(5y)330.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5YN/A
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%200%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5YN/A
EBIT growth 1Y-0.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.27%
OCF growth 3YN/A
OCF growth 5YN/A